Admetsys

Admetsys is pioneering automated clinical robotics for critical care, targeting two major challenges: precise glycemic control and early sepsis detection. Its system combines the PrecisionOne™ autonomous controller with the Intravenous Laboratory™ for continuous, blood-based biosensing, aiming to eliminate manual interventions and improve standard of care. With FDA Breakthrough Designation and CE Mark approval for PrecisionOne, the company is advancing toward commercialization with strong clinical trial data showing superior glucose control and safety compared to manual methods. Admetsys addresses significant ICU burdens including staff shortages, cost pressures, and variable patient outcomes.

Integrated clinical robotics system combining the PrecisionOne™ AI-driven automation controller for closed-loop glucose regulation and the Intravenous Laboratory™ for real-time, continuous, blood-based biosensing of multiple analytes (glucose, lactate, hematocrit, temperature) with zero blood loss.

Competition includes companies developing automated insulin delivery for the inpatient setting (e.g., Roche, others in development) and makers of continuous glucose monitors (e.g., Dexcom, Abbott), though Admetsys differentiates with its blood-based sensing, multi-analyte diagnostics, and fully closed-loop therapeutic automation specifically designed for critical care pathophysiologies.